title: New insights into subtypes of invasive bladder cancer: considerations of the clinician.
authors.affiliation: Departments of Urology and Cancer Biology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: dmcconke@mdanderson.org.
authors.forename: David J
authors.initials: DJ
authors.lastname: McConkey
authors.affiliation: Departments of Urology and Cancer Biology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
authors.forename: Woonyoung
authors.initials: W
authors.lastname: Choi
authors.affiliation: Departments of Urology and Cancer Biology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
authors.forename: Colin P N
authors.initials: CP
authors.lastname: Dinney
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D015972:Gene Expression Regulation, Neoplastic / Q000235:genetics*; D006801:Humans; D008727:Methotrexate / Q000627:therapeutic use; D046228:Microarray Analysis; D058990:Molecular Targeted Therapy; D009130:Muscle, Smooth / Q000473:pathology; D009361:Neoplasm Invasiveness / Q000473:pathology; D011379:Prognosis; D016019:Survival Analysis; D016896:Treatment Outcome; D001749:Urinary Bladder Neoplasms / Q000145:classification* / Q000235:genetics* / Q000401:mortality / Q000628:therapy; D014747:Vinblastine / Q000627:therapeutic use
chemical_list: D014747:Vinblastine; D004317:Doxorubicin; D002945:Cisplatin; D008727:Methotrexate